Philip Lowry, MD

Care Provider Overall: 
5
Provider Reviews: 
112
  • Clinical Details
  • Education
  • Clinical Trials
Hospital Privileges: 
  • Guthrie Robert Packer Hospital
Clinical Interests: 
  • Colorectal Cancer
  • Lung Cancer

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of Recommending Care Provider: 
5
Patients' Confidence in Care Provider: 
5
Time Care Provider Spent with Patient: 
5
Care Provider Spoke Using Clear Language: 
5
Care Provider Efforts to Include in Decisions: 
5
Care Provider's Concern for Questions and Worries: 
5
Care Provider's Explanations of Condition/Problem: 
5
Care Provider Information About Medications: 
5
Care Provider Instructions for Follow-Up Care: 
5
Care Provider's Friendliness and Courtesy: 
5
Residency: 
  • University of Virginia, Charlottesville, Va.
Certification: 
  • American Board of Internal Medicine/Hematology
  • American Board of Internal Medicine/Oncology
Education: 
  • Yale University School of Medicine, New Haven, Conn.
Fellowship: 
  • University of Virginia, Charlottesville, Va.
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02750826
Title: Alliance A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02927249
Title: A011502, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lowry MD, Philip
Sponsor: NRG
Details (Identifier #): NCT02488967
Title: NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT02154490
Title: Lung-MAP: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sponsor: Roche
Details (Identifier #): NCT02624986
Title: BH29812, A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with idasanutlin in patients with relapsed or refractory follicular lymphoma and obinutuzumab or rituximab in combination with idasanutlin in patients with relapsed or refractory diffuse large B-cell lymphoma
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT02595905
Title: S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lowry MD, Philip
Sponsor: Roche
Details (Identifier #): NCT03135262
Title: BH39147, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination with Idasanutlin and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT03418961
Title: S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02869789
Title: BMS CA209-817, A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT03090737
Title: "An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants with Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least Once Prior Systemic Regimen": CA209-907-022
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02115282
Title: E2112, A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02201992
Title: E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02445391
Title: EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02595944
Title: EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Title: Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT02224781
Title: EA6134, A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Department: Oncology
Diagnosis: Genito-urinary - Prostate
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG-ACRIN
Details (Identifier #): NCT03419234
Title: Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: NCI
Details (Identifier #): NCT02465060
Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Guthrie Patient: June 2018
Explains everything thoroughly. Never 'talks down' to patient. Answers all questions. His confidence is reassuring.
Guthrie Patient: June 2018
Dr. Lowery is one of the most impressive doctors I have ever met. His breadth & depth knowledge of my condition and insight into what I was thinking 'blew me away'. Guthrie is fortunate to have such an excellent physician with his in site and experience. I trust him explicitly with my well being.
Guthrie Patient: May 2018
My first visit w *Dr. Lowry made me feel relaxed. Very easy to understand.
Guthrie Patient: April 2018
This was our first visit with Dr. Lowry. I can't think of a more perfect doctor to help my husband through this crisis. My DIL is a nurse at your organization and this is the first time she did not have something negative to say about what was/was not discussed during the appointment. Three people left Dr. Lowry's office all feeling the same. He is probably the best doctor we have ever had. And as I said, he is just perfect to get my husband through his current crisis. This is the first time, I have every felt the doctor had actually taken the time to read *name removed*'s chart to know his history. You had best get on your knees and beg him to stay.
Guthrie Patient: March 2018
this was my first visit to him - he was very understanding, explained everything, easy to talk to and ask questions - I will continue to see him
Guthrie Patient: March 2018
*Dr. Lowry was very understanding about my choice of follow-up treatment.
Guthrie Patient: March 2018
excellent
Guthrie Patient: March 2018
still waiting for second opinion referral going on 2 weeks. I ask for it daily. apparently he's too busy but told me he would write one
Guthrie Patient: January 2018
We had a list of questions to ask Dr. Lowry- I saved them to the end of our visit. By the time it was time to ask questions- I realized he had already provided info/answers to 3/4's of them!-we loved that. He made us feel very comfortable with discussing our serious health issues and we are very glad to have him as our oncologist. We would HIGHLY recommend him.
Guthrie Patient: January 2018
I'm so happy to have Dr. Lowry for my oncologist! I've been to doctors at Johns Hopkins and also at Columbia University Medical Center and as good as they are, I wouldn't trade Dr. Lowry for any of them. He has a positive attitude and a great bedside manner - he shows concern, but also has a sense of humor, and is very knowledgeable about treatment and options. I know he's booked solid, but he never makes me feel rushed or that he doesn't have time for my questions. He's the best!